Cogent

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on developing precision therapies for genetically defined diseases. The company's lead program is bezustertinib (formerly CGT9486), a highly selective tyrosine kinase inhibitor designed to target the KIT D816V mutation, which is the primary driver of systemic mastocytosis. Bezustertinib is currently being evaluated in the Phase 3 SUMMIT trial for non-advanced systemic mastocytosis and the Phase 3 PEAK trial for gastrointestinal stromal tumors (GIST). Beyond its lead asset, Cogent is advancing a pipeline of next-generation small molecule inhibitors targeting FGFR2 and ErbB2 for various solid tumor indications. The company leverages its internal research team in Boulder, Colorado, to discover and develop potent, selective inhibitors that address unmet needs in oncology and rare diseases.